Holen Sie sich die Stockscreener-App
11.17
3.91%
0.42
Handel nachbörslich:
11.33
0.16
+1.43%
Schlusskurs vom Vortag:
$10.75
Offen:
$10.75
24-Stunden-Volumen:
1.14M
Relative Volume:
0.69
Marktkapitalisierung:
$1.79B
Einnahmen:
$394.50M
Nettoeinkommen (Verlust:
$-2.63M
KGV:
-558.50
EPS:
-0.02
Netto-Cashflow:
$70.29M
1W Leistung:
+17.21%
1M Leistung:
+0.72%
6M Leistung:
-21.61%
1J Leistung:
-10.28%
1-Tages-Spanne:
$10.61
$11.26
1-Wochen-Bereich:
$10.20
$11.62
52-Wochen-Spanne:
$8.635
$15.69
Certara Inc Stock (CERT) Company Profile
Firmenname
Certara Inc
Sektor
Branche
Telefon
(415) 237-8272
Adresse
4 RADNOR CORPORATE CENTER, SUITE 350, RADNOR
Vergleichen Sie CERT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CERT
Certara Inc
|
11.17 | 1.73B | 394.50M | -2.63M | 70.29M | -0.02 |
|
VEEV
Veeva Systems Inc
|
279.18 | 45.01B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
69.63 | 11.53B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
64.02 | 11.58B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
89.27 | 8.04B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
35.35 | 6.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Certara Inc Stock (CERT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-03 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-05-08 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-02-27 | Eingeleitet | TD Cowen | Buy |
| 2024-09-27 | Hochstufung | UBS | Neutral → Buy |
| 2024-04-10 | Hochstufung | KeyBanc Capital Markets | Sector Weight → Overweight |
| 2024-04-04 | Eingeleitet | JMP Securities | Mkt Perform |
| 2024-02-26 | Eingeleitet | Leerink Partners | Market Perform |
| 2023-12-07 | Eingeleitet | UBS | Neutral |
| 2023-12-05 | Eingeleitet | KeyBanc Capital Markets | Sector Weight |
| 2023-08-22 | Herabstufung | Jefferies | Buy → Hold |
| 2023-08-10 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-04-12 | Eingeleitet | Stephens | Overweight |
| 2023-04-03 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-14 | Herabstufung | Robert W. Baird | Outperform → Neutral |
| 2022-09-08 | Eingeleitet | Berenberg | Buy |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-01 | Eingeleitet | Piper Sandler | Overweight |
| 2022-01-11 | Hochstufung | Jefferies | Hold → Buy |
| 2021-08-05 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-07-23 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-03-03 | Eingeleitet | Barclays | Overweight |
| 2021-01-06 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2021-01-05 | Eingeleitet | BofA Securities | Buy |
| 2021-01-05 | Eingeleitet | Credit Suisse | Neutral |
| 2021-01-05 | Eingeleitet | Jefferies | Hold |
| 2021-01-05 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Certara Inc Aktie (CERT) Neueste Nachrichten
Certara’s SWOT analysis: biosimulation firm’s stock faces growth hurdles - Investing.com
Certara (CERT) Is Up 9.0% After Simcyp Simulator Wins EMA Qualification and Q2 Sales Rise—Has the Bull Case Changed? - simplywall.st
Certara Second Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Certara, Inc. Reports Strong Q2 2025 Earnings Growth - TipRanks
Certara, Inc. Reports Strong Q2 2025 Growth - TipRanks
Here's Why It's Unlikely That Certara, Inc.'s (NASDAQ:CERT) CEO Will See A Pay Rise This Year - 富途牛牛
Can Traders Expect Breakout From Certara Inc. This WeekLow Capital High Return Stock Plans Reviewed - beatles.ru
Certara signals full year 8–10% revenue growth outlook as AI and QSP momentum builds - MSN
Certara, Inc. (NASDAQ:CERT) Q2 2025 Earnings Call Transcript - Insider Monkey
Certara's Financials Obscure Share Price Momentum: What's Next? - AInvest
Certara, Inc.'s (NASDAQ:CERT) Financials Are Too Obscure To Link With Current Share Price Momentum: What's In Store For the Stock? - Yahoo Finance
Certara, Inc. (CERT) Q2 Earnings Miss Estimates - MSN
Certara 2025 Q2 Earnings Narrows Losses, Reports 84.3% Reduction in Net Loss - AInvest
Navigator Holdings Ltd. shares fall 1.00% intraday after Certara, Inc. reports Q2 2025 earnings. - AInvest
Certara, Inc. (CERT): A Bull Case Theory - Insider Monkey
UBS Maintains Certara (CERT) Rating, Lowers Price Target to $15. - GuruFocus
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns By Investing.com - Investing.com South Africa
Leerink Partners lowers Certara stock price target to $11.50 on valuation concerns - Investing.com Nigeria
Certara Surges 15.58% Amid Volatile Intraday Action—What’s Fueling the Rally? - AInvest
UBS Adjusts Price Target on Certara to $15 From $17.50, Maintains Buy Rating - MarketScreener
Earnings call transcript: Certara misses Q2 2025 EPS forecast, stock dips By Investing.com - Investing.com South Africa
Earnings call transcript: Certara misses Q2 2025 EPS forecast, stock dips - Investing.com
Certara’s Mixed Signals: Hold Rating Amidst Growth Potential and Strategic Uncertainty - TipRanks
Certara's Q2 Results and Strategic Positioning Support Buy Rating with $16 Price Target - AInvest
Certara (CERT) Q2 Revenue Jumps 12% - AOL.com
Decoding Certara Inc (CERT): A Strategic SWOT Insight - GuruFocus
Certara's AI-Driven Biosimulation Platform: A Catalyst for Drug Development Transformation - AInvest
Certara's Q2 2025 Earnings: Strategic Resilience in a Shifting Biosimulation Landscape - AInvest
Certara's Q2 2025 Earnings Call: Contradictory Signals on Market Potential, Demand Dynamics, and Retention Rates - AInvest
Certara Expects Full-Year Revenue Growth of 8-10% on AI, QSP Momentum - AInvest
Certara Grows In Q2 But Falls Short Of Analyst Estimates - Finimize
Certara Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Press Release: Certara Reports Second Quarter 2025 Financial Results - 富途牛牛
Certara Q2 2025 slides: 12% revenue growth despite swing to net loss By Investing.com - Investing.com South Africa
Certara Q2 adjusted EPS misses estimates - MarketScreener
Certara Q2 2025 slides: 12% revenue growth despite swing to net loss - Investing.com UK
CERT SEC FilingsCertara, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Certara Earnings: Software Revenue Surges 22% as Biosimulation Demand Drives Record Q2 Performance - Stock Titan
Visual analytics tools that track Certara Inc. performanceSwing Reversal Forecast Based on Patterns - Newser
Navigator Holdings Ltd. shares rise 1.84% intraday after Certara's Simcyp Simulator receives EMA qualification. - AInvest
The PBPK Revolution: How Certara's Simcyp Simulator is Reshaping Drug Development and Regulatory Acceptance - AInvest
Certara Simcyp Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - MarketScreener
Certara Obtains European Medicines Agency Qualification for Biosimulation Software - MarketScreener
Certara Simcyp® Simulator Becomes First and Only Software Platform to Receive EMA Qualification Opinion for PBPK Modeling - The Manila Times
Certara's Simcyp® Simulator Achieves EMA Qualification for Regulatory Submissions in the EU - Quiver Quantitative
Certara - Via Ritzau
Why is Certara Inc. stock attracting strong analyst attentionUnlock daily market insights for better trades - Jammu Links News
What institutional investors are buying Certara Inc. stockUnlock powerful portfolio optimization tools - Jammu Links News
What markets is Certara Inc. expanding into Is KREF stock a good long term investment optionExceptional profit potential - Jammu Links News
What are analysts’ price targets for Certara Inc. in the next 12 monthsBreakthrough financial growth - Jammu Links News
What is the risk reward ratio of investing in Certara Inc. stockNavigate market volatility with smart strategies - Jammu Links News
Finanzdaten der Certara Inc-Aktie (CERT)
Umsatz
Nettogewinn
Free Cashflow
ENV
11.17%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):